8-K: Treace Medical Reports Q2 2025 Results, Launches New Bunion Tech

Treace Medical Concepts reported improved second quarter 2025 financial results, including 7% revenue growth and reduced net loss, alongside the full market release of three new bunion technologies.

Summary

• Revenue for the second quarter of 2025 was $47.4 million, representing an increase of 7% compared to $44.5 million in the second quarter of 2024.
• Net loss improved by 18% to $(17.4) million in the second quarter of 2025, compared to $(21.2) million in the same period in 2024.
• Adjusted EBITDA improved by 58% to $(3.6) million in the second quarter of 2025, compared to $(8.7) million in the same period in 2024.
• The company announced the full market release of the Nanoplasty and Percuplasty 3D MIS Osteotomy Systems, and the SpeedMTP MTP Fusion System.
• Align3D four-year clinical data was published in The Journal of Foot & Ankle Surgery, demonstrating long-term positive patient outcomes for the Lapiplasty system.
• Total liquidity as of June 30, 2025, was $90.7 million, comprised of $69.3 million of cash, cash equivalents, and marketable securities, and $21.4 million of availability under the revolving loan facility.
• Cash usage decreased by 55% in the second quarter 2025 and 78% year-to-date compared to the prior year.
• Full-year 2025 revenue guidance was reaffirmed at $224 million to $230 million, representing growth of 7% to 10% over 2024.
• The company continues to expect breakeven Adjusted EBITDA for the full-year 2025.

Sentiment

Score: 7

Explanation: The company demonstrated strong operational improvements with significant reductions in net loss and Adjusted EBITDA loss, coupled with robust revenue growth and successful new product launches. The reaffirmation of full-year guidance and reduced cash burn are positive indicators, despite still operating at a net loss.

Positives

• Revenue grew 7% to $47.4 million in Q2 2025.
• Net loss improved by 18% to $(17.4) million in Q2 2025.
• Adjusted EBITDA improved by 58% to $(3.6) million in Q2 2025.
• Successfully launched three new bunion technologies: Nanoplasty, Percuplasty 3D MIS Osteotomy Systems, and SpeedMTP MTP Fusion System.
• Published positive four-year clinical data for the Align3D (Lapiplasty) system, distinguishing it with long-term prospective data.
• Expanded global patent portfolio to 117 granted patents and 163 pending applications.
• Significantly reduced cash usage by 55% in Q2 2025 and 78% year-to-date compared to the prior year.
• Reaffirmed full-year 2025 revenue guidance of $224 million to $230 million, indicating continued growth expectations.
• Reaffirmed expectation of breakeven Adjusted EBITDA for full-year 2025.

Negatives

• The company reported a net loss of $(17.4) million in Q2 2025.
• Gross margin slightly decreased to 79.7% in Q2 2025 from 80.2% in Q2 2024.
• The company is still operating at an Adjusted EBITDA loss of $(3.6) million.

Risks

• Ability to effectively respond to and mitigate the impact of challenges in the current market environment, including increased competition and accelerating adoption of MIS osteotomy solutions.
• Potential impact from evolving tariffs, changes in trade policies, or economic uncertainty.
• Ability to protect and enforce intellectual property rights, including through ongoing patent infringement and unfair competition suits.
• Success in defending against securities class actions and infringement of intellectual property by third parties, including competitors.
• Seasonality, including expected accelerating revenue growth rates for the 2025 third and fourth quarters, which implies potential variability in quarterly performance.
• Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, meaning actual results may differ materially from expectations.

Future Outlook

The company reaffirms its full-year 2025 revenue guidance of $224 million to $230 million, representing 7% to 10% growth over 2024, and continues to expect breakeven Adjusted EBITDA for the full year. Management anticipates increased product adoptions, continued execution of strategic initiatives, and an expanded market position and growth rates, with expected accelerating revenue growth rates for the 2025 third and fourth quarters.

Management Comments

• The second quarter was highlighted by solid progress in further addressing the needs of surgeons and patients with our expanded portfolio of best-in-class 3D bunion solutions as we delivered strong financial results and made meaningful progress on our strategic initiatives.
• We are extremely pleased with the surgeon enthusiasm and patient outcomes experienced during the limited market releases of our Nanoplasty, Percuplasty, and SpeedMTP systems.
• We believe the demand for these new technologies, combined with our flagship Lapiplasty and Adductoplasty systems, will establish Treace as the preeminent surgical bunion technology provider.
• We are excited to bring this comprehensive suite of bunion technologies to market and drive the next phase of growth for the Company.

Industry Context

Treace Medical Concepts operates in the medical technology sector, specifically focusing on the surgical treatment of bunions and related midfoot deformities. The company aims to drive a fundamental shift in the standard of care for these conditions, which affect approximately 67 million Americans, with an estimated 1.1 million annual surgical candidates. Its Lapiplasty 3D Bunion Correction System addresses the root cause of bunions by correcting the deformity in three planes and securing the unstable joint, distinguishing itself with four-year multicenter, prospective published clinical data. The expansion into minimally invasive osteotomy procedures (Nanoplasty, Percuplasty) and MTP fusion (SpeedMTP) reflects a broader industry trend towards less invasive and more comprehensive solutions in orthopedic surgery.

Comparison to Industry Standards

• Lapiplasty is highlighted as the only commercial surgical bunion system supported by four-year multicenter, prospective published data, suggesting a stronger evidence base compared to other market offerings.
• The expansion into Nanoplasty, Percuplasty 3D MIS Osteotomy Systems, and SpeedMTP MTP Fusion System positions the company to offer a comprehensive suite of bunion technologies, aiming to become the 'preeminent surgical bunion technology provider' in the competitive foot and ankle market.

Legal Proceedings

• Litigation costs of $1.055 million in Q2 2025 and $1.510 million year-to-date relate to patent infringement lawsuits.
• The company faces risks related to its success in defending against securities class actions and infringement of its intellectual property by third parties, including competitors.

Stakeholder Impact

• Shareholders: Positive financial results (revenue growth, reduced losses), new product launches, and reaffirmed guidance could lead to increased investor confidence and potential share price appreciation.
• Employees: Continued growth and strategic initiatives may indicate job stability and potential for expansion within the company.
• Customers (Surgeons): The expanded portfolio of bunion technologies (Nanoplasty, Percuplasty, SpeedMTP) provides more options and potentially better patient outcomes, enhancing surgeon satisfaction and adoption.
• Patients: New technologies and published clinical data (Align3D) aim to improve surgical outcomes and quality of life for individuals suffering from bunions and related midfoot deformities.

Next Steps

• Host a conference call on August 7, 2025, at 4:30 p.m. ET to discuss Q2 2025 financial results.
• Host an Investor Day on September 3, 2025, in New York, NY, to highlight new products and experiences with the expanded technology portfolio.
• Continue to execute strategic initiatives to increase procedure volumes, expand surgeon customer base and utilization rate, and increase procedure penetration and market share.
• Expand clinical evidence for its products.
• Protect and enforce intellectual property rights, including through ongoing litigation.
• Anticipate accelerating revenue growth rates for the 2025 third and fourth quarters.

Key Dates

Recommendation

While the company shows strong operational improvements, including revenue growth, reduced losses, and new product launches, it is still operating at a net loss and an Adjusted EBITDA loss. The reaffirmed guidance for breakeven Adjusted EBITDA for the full year is positive, but the company is still in a growth phase with associated risks, including competition and ongoing litigation costs. The significant reduction in cash usage is a good sign for liquidity management. For a seasoned investor, the current performance indicates progress but not yet consistent profitability, suggesting a 'hold' position to observe continued execution on strategic initiatives and sustained improvement towards profitability.

Keywords

Medical Technology, Bunion Correction, Lapiplasty, Orthopedics, Foot & Ankle Surgery, Surgical Devices, Minimally Invasive Surgery, Financial Results, SEC Filing, TMCI